tracken
Mirum Pharmaceuticals Inc Aktie News
Neutral
Business Wire
●
2 Tage alt
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025.
Neutral
Business Wire
●
20 Tage alt
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Neutral
Business Wire
●
etwa 2 Monate alt
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Peetz - CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healt...
Neutral
Business Wire
●
etwa 2 Monate alt
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded in...
Neutral
Business Wire
●
2 Monate alt
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Positiv
Seeking Alpha
●
3 Monate alt
Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue growth, with approvals in both the U.S. and Europe to treat symptoms of rare liver diseases. The analyst community remains unanimously bullish on the stock, and more than a half dozen analyst firms ...
Neutral
Seeking Alpha
●
3 Monate alt
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Eric H. Bjerkholt - Chief Financial Officer Joanne M.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
